(AMLX) Amylyx Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMLX) Amylyx Pharmaceuticals, Inc. Complete Analysis Pack
See the Bigger Picture
This Amylyx Pharmaceuticals, Inc. BCG Matrix is a company-specific strategy tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 approved products
At the end of 2025, Amylyx Pharmaceuticals, Inc. had 0 FDA-approved commercial products, so its Stars bucket was empty. With no approved drug driving sales, it had no asset leading a growing market with durable share. That left Amylyx without the revenue base usually needed to support a Star position.
No market-share leader
Amylyx Pharmaceuticals had no market-share leader in 2026: Relyvrio was withdrawn in April 2024 after its Phase 3 failure, so there was no U.S. sales base to defend. 2025 revenue fell to near zero from Relyvrio, and no other asset had reached commercial leadership.
Clinical-stage only
Amylyx Pharmaceuticals, Inc. was still a clinical-stage story, with value tied to pipeline data, not durable sales. The company kept spending on R&D, while commercialization stayed limited after AMX0035 was pulled from the market in 2024. That means the assets could still scale fast, but they were not yet true "stars" in BCG terms.
No recurring product revenue
At end-2025, Amylyx Pharmaceuticals, Inc. had no marketed therapy generating recurring product revenue, and product sales were $0 after the AMX0035/Azur withdrawal. Without revenue growth, it could not fit the Star bucket; value depended on pipeline readouts, not a stable franchise.
- No marketed product sales in 2025
- Product revenue = $0
- Pipeline drove valuation
- No Star without growth
R&D-led portfolio
Amylyx Pharmaceuticals, Inc.’s portfolio was centered on neurodegeneration research programs, so it fits a pipeline posture, not a high-share commercial one. In BCG terms, that means no Star was present: the value sat in research bets, not in a scaled, dominant market position.
That profile is typical of a company spending for future upside, with commercial traction still too thin to support a Star label. The key signal is simple: innovation was the asset, not market share.
- No Star business was present
- Neurodegeneration pipeline drove value
- R&D posture, not scale posture
Amylyx Stays a Pipeline Story, Not a Revenue Story
At end-2025, Amylyx Pharmaceuticals, Inc. had no FDA-approved product and no recurring product sales, so the Stars bucket stayed empty. 2025 product revenue was $0, and value still came from pipeline readouts, not a dominant commercial asset.
| Metric | 2025 |
|---|---|
| FDA-approved products | 0 |
| Product revenue | $0 |
| Star status | None |
What is included in the product
Detailed Word Document
Amylyx’s BCG matrix maps its pipeline and approved drugs by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG snapshot of Amylyx Pharmaceuticals, Inc. to spot each business unit’s quadrant and pain points at a glance.
Reference Sources
Lists credible sources for Amylyx Pharmaceuticals, Inc. to validate claims fast and support confident, traceable decision-making.
Cash Cows
0 mature franchises
By the end of 2025, Amylyx Pharmaceuticals, Inc. had 0 mature franchises in the Cash Cows quadrant. Cash cows need a long-lived, low-growth product with strong share, and the ALS franchise was withdrawn, leaving no legacy brand to harvest. The quadrant was empty, with no durable cash generator to support the portfolio.
No steady product cash flow
After Amylyx Pharmaceuticals, Inc. withdrew Relyvrio in April 2024, it had no marketed drug generating repeat sales in FY2025. That means there was no cash-cow product to fund the pipeline, sales force, or trials. The business instead depended on financing and development capital to keep operating.
No royalty stream
Amylyx reported no royalty income in 2025, so it was not leaning on a large external royalty book. Its cash generation was tied to product sales, not a mature in-market franchise with steady, low-risk harvest cash. So this BCG cell fits: there was no milking asset to defend.
No dividend funding asset
Amylyx Pharmaceuticals, Inc. had no cash cow in late 2025: no marketed product was funding overhead, debt service, or dividends. The company was still in investment mode, with cash being used for R&D and pipeline buildout instead of payouts. That makes this BCG bucket a clear fit: low cash harvest, high reinvestment.
- No dividend-funded asset in late 2025
- No product financing overhead or debt service
- Cash stayed tied to R&D spending
- Company remained in investment mode
Development cash used for R&D
Amylyx Pharmaceuticals, Inc. had no true cash cow here: available cash was being pushed into R&D and pipeline work, not milking a mature, low-growth asset for profit. In BCG terms, that means the portfolio was still in investment mode, with no self-funding, high-share cash engine to support the rest. That is why development cash use points to "question mark" behavior, not "cash cow" behavior.
- Cash funded pipeline advancement
- No mature profit center
- Not self-funding
- R&D drained, not generated, cash
Amylyx Had No Cash Cow in FY2025
By FY2025, Amylyx Pharmaceuticals, Inc. had no Cash Cow: Relyvrio was withdrawn in April 2024, no marketed drug generated repeat sales, and royalty income was zero. Cash was still going to R&D and pipeline work, so the business was not harvesting a mature, low-growth asset.
| FY2025 | Signal |
|---|---|
| 0 | Cash cows |
| 0 | Royalty income |
| No | Marketed drug |
Preview Before You Purchase
Amylyx Pharmaceuticals, Inc. Reference Sources
This Amylyx Pharmaceuticals, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. It includes the full, professionally formatted analysis with no hidden changes. What you see here is what you download. Ready for immediate use in research, planning, or presentation.
Dogs
Relyvrio/ALBRIOZA
Relyvrio/ALBRIOZA was Amylyx Pharmaceuticals, Inc. only marketed product, but it was pulled after the PHOENIX ALS trial missed its primary endpoint in September 2024. Sales went to zero after the withdrawal, so in BCG terms it fits a classic dog: low share, low growth, and no remaining cash engine. That collapse also removed Amylyx Pharmaceuticals, Inc. core revenue base, which had been almost entirely tied to one asset.
PHOENIX ALS failure
PHOENIX, a phase 3 ALS study, did not confirm benefit for Amylyx Pharmaceuticals, Inc.'s AMX0035, so the drug lost its core growth driver. ReLYVRIO generated $381.7 million in 2023 sales, but the PHOENIX miss led to its U.S. and Canada withdrawal in 2024, erasing the commercial case. In BCG terms, this moved the ALS asset into a Dogs profile.
ALS sales wind-down
The ALS sales wind-down is a Dog in Amylyx Pharmaceuticals, Inc. BCG Matrix terms. After the 2024 global withdrawal of AMX0035, the branded ALS sales engine was shut down, and by end-2025 there was no active ALS commercialization platform left to drive growth.
Canada exit
ALBRIOZA was Amylyx Pharmaceuticals, Inc.'s Canadian brand, and the Canada exit wiped out its mature market position there. In BCG terms, that makes it a dead-end commercial asset: no growth runway, shrinking strategic value, and no visible 2025 revenue base to defend after the withdrawal.
- ALBRIOZA was the Canadian brand.
- Withdrawal ended mature-market cash flow.
- Dead-end asset, not a growth driver.
Stranded launch costs
Relyvrio was shut down after phase 3 failure, so Amylyx Pharmaceuticals, Inc. had sales, manufacturing, and medical support assets sitting idle. In 2023, the company reported $261.0 million in net product revenue from Relyvrio, then took a major write-down and exited the market, leaving stranded launch costs that are hard to recover. Dogs like this usually trap cash and add little to no growth.
- Idle sales force and field support
- Unused manufacturing and supply spend
- High exit losses, low resale value
Amylyx’s ALS Asset Turns Into a Dog After Relyvrio’s Collapse
Amylyx Pharmaceuticals, Inc.'s ALS asset is a Dog: Relyvrio/ALBRIOZA was withdrawn after PHOENIX missed its endpoint, so the company lost its only product-led growth engine.
Net product revenue was $261.0 million in 2023, then fell to zero after the 2024 exit, leaving stranded sales, manufacturing, and support costs.
| Metric | Value |
|---|---|
| 2023 net product revenue | $261.0M |
| PHOENIX result | Primary endpoint missed |
| Post-withdrawal revenue | $0 |
Question Marks
AMX0114 in ALS
AMX0114 was Amylyx Pharmaceuticals, Inc.'s next ALS program, aimed at a new neurodegeneration target and still in early clinical testing, so it had 0 market share. In BCG terms, it was a clear Question Mark: high future upside, but no sales yet and no proof of scale. If it worked, it could move toward Star status or stay a small niche asset.
Avexitide in PBH
Avexitide is aimed at post-bariatric hypoglycemia, a rare niche tied to the roughly 200,000 U.S. bariatric surgeries done each year; severe PBH is still underserved, with published estimates around 1% to 3% of patients. Amylyx Pharmaceuticals, Inc. had no commercial share at end-2025, so it sits in the Question Mark bucket: high upside, no revenue base. Late-stage data could re-rate the asset fast if efficacy and safety hold.
Avexitide in CHI
Avexitide in congenital hyperinsulinism targets an ultra-rare pediatric disease, affecting about 1 in 28,000 to 50,000 births, so the addressable market is small but clinically critical. With few approved options and share still being built, Amylyx Pharmaceuticals, Inc. is still investing to prove uptake and fit. That makes Avexitide a classic question mark in the BCG matrix: high need, low current share.
AMX0035 in Wolfram syndrome
AMX0035 in Wolfram syndrome is still a development bet, not a revenue driver. Wolfram syndrome is ultra-rare, with an estimated prevalence of about 1 in 500,000 to 1,000,000 people, so the commercial upside is real but the base is tiny. Amylyx had no established 2025/2026 revenue from this program.
- Rare-disease upside
- No sales base yet
- Early-stage pipeline risk
AMX0035 in PSP
AMX0035 was also tested in progressive supranuclear palsy (PSP), a rare tau-driven disease with no approved disease-modifying therapy and median survival often cited at 6-10 years. That made PSP a high-need market, but Amylyx still had to prove clear efficacy and payer uptake before it could matter commercially.
- PSP has no approved cure.
- Clinical proof was still the hurdle.
- Adoption depended on outcomes and access.
Amylyx’s Question Mark Pipeline: High Upside, No 2025 Sales Yet
Amylyx Pharmaceuticals, Inc.’s Question Marks had high upside but no 2025 sales base: AMX0114, Avexitide, and AMX0035 in rare diseases all stayed in early or mid development, with zero market share and no proven scale. That fits BCG Question Mark status because the assets address small but unmet markets, yet still need late-stage data and adoption to turn into revenue. End-2025, the key test was proof, not size.
AMX0114 had no commercial share and remained an ALS bet, while Avexitide targeted post-bariatric hypoglycemia and congenital hyperinsulinism, both niche rare-disease markets with limited competition. AMX0035 in Wolfram syndrome and PSP also stayed pre-revenue, so Amylyx Pharmaceuticals, Inc. was still funding future optionality rather than harvesting cash.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.